

Serveur Académique Lausannois SERVAL [serval.unil.ch](http://serval.unil.ch)

## Author Manuscript

Faculty of Biology and Medicine Publication

This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Published in final edited form as:

**Title:** Blood culture-based diagnosis of bacteraemia: state of the art.

**Authors:** Opota O, Croxatto A, Prod'hom G, Greub G

**Journal:** Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases

**Year:** 2015 Apr

**Issue:** 21

**Volume:** 4

**Pages:** 313-22

**DOI:** 10.1016/j.cmi.2015.01.003

In the absence of a copyright statement, users should assume that standard copyright protection applies, unless the article contains an explicit statement to the contrary. In case of doubt, contact the journal publisher to verify the copyright status of an article.

1 Blood Culture-Based Diagnosis of Bacteremia: State of the Art.

2 Onya Opota<sup>a</sup>, Antony Croxatto<sup>a</sup>, Guy Prod'hom<sup>a</sup> and Gilbert Greub<sup>ab</sup>.

3

4 Institute of Microbiology<sup>a</sup> and Infectious Diseases Service<sup>b</sup>, University of Lausanne and University

5 Hospital Center, Lausanne, Switzerland

6

7 Running title: Diagnostic of bacteremia

8

9 Corresponding author:

10 Gilbert Greub,

11 Institute of Microbiology,

12 University of Lausanne and University Hospital Center,

13 Bugnon 44, 1010 Lausanne,

14 Switzerland.

15 Phone +41 (0)21 314 4979

16 Fax +41 (0)21 314 4060

17 E-mail : [Gilbert.Greub@chuv.ch](mailto:Gilbert.Greub@chuv.ch)

18

19

20 Keywords: bacteremia, diagnostic, blood-culture, bacterial pellet, bloodstream infection

21

## 22 **Abstract**

23 Blood culture remains the best approach to identify the incriminated microorganisms when a bloodstream  
24 infection (BSI) is suspected, and to guarantee that the antimicrobial treatment is adequate. Major  
25 improvements have been made in the last years to increase the sensitivity and the specificity and to reduce  
26 the time to identification of microorganisms recovered from blood cultures. Among others, the introduction  
27 in clinical microbiology laboratories of the matrix-assisted laser desorption ionization time-of-flight mass  
28 spectrometry (MALDI-TOF MS) technology revolutionized the identification of microorganisms whereas  
29 the introduction of nucleic-acid based methods such as DNA hybridization or POCT-PCR significantly  
30 reduce the time to results. Together with traditional antibiotic susceptibility testing (AST), new rapid  
31 methods for the detection of resistance mechanisms respond to major epidemiological concern such as  
32 MRSA, ESBL or carbapenemases.

## 33 **Introduction**

34 Bloodstream infections (BSIs) are severe diseases characterized by a high morbidity and mortality, which  
35 is directly related with the delay in the administration of the first adequate anti-infectious agent [1-7].  
36 Empirical anti-infectious treatments are chosen on the basis of the clinical and epidemiological data and  
37 are started immediately after the sampling of the blood vials; however until microbiological documentation,  
38 their adequacy cannot be guaranteed [8-10]. Microbiological investigations – identification of the causative  
39 agent and antibiotic susceptibility test (AST) - are thus very important: 1) to adjust the anti-infectious  
40 therapy and to avoid inefficient treatment, 2) to reduce the spectrum of the anti-infectious therapy in order  
41 to limit the selection of resistant strains and 3) to limit the toxicity and negative impact on beneficial bacteria  
42 of some broad spectrum molecules or combined therapy. In adults the quantity of microbes present in the  
43 blood during BSIs ranges from 1 to 10 cfu per ml [11-14] to  $1 \times 10^3$  and  $1 \times 10^4$  [15]. In children the bacterial  
44 load during BSI might be higher. Blood cultures currently represent the main method to determine the  
45 etiology of a BSI because they are highly sensitive and easy to perform. The sensitivity of blood culture is  
46 largely due to the volume of the sample. For adults one blood sampling generally represent up to 20 ml of  
47 blood used to inoculate 2 vials (one aerobic vial and one anaerobic vial). Before antibacterial treatment 2  
48 to 4 blood cultures, i.e. 40 ml to 80 ml of blood are necessary to detect a causative agent in 80% to 96% of  
49 bacteremia [16, 17]. In clinical practice however, the sampling is often limited to 2 blood cultures.  
50 Nevertheless, approximately 50 % of the BSI remains blood culture negative [18, 19] and further  
51 improvements may be foreseen.

## 52 **Blood culture sampling and technologies**

53 Standard vials containing rich media have been designed for aerobic and anaerobic growth conditions,  
54 respectively. They are dedicated for up to 10ml ml of blood. However, because of the difficulty to obtain  
55 large volume of blood, specific pediatric blood vials have been designed for the culture of volume lower

56 than 3ml. To neutralize antibiotics given prior sampling charcoal or resins have been introduced in specific  
57 vials. Lytic agents added in some growth media promote the recovery and growth of organisms that have  
58 been endocytosed by phagocytes. Standard incubation time is around 5-7 days which is sufficient for the  
59 recovery of the majority of organisms including HACEK bacteria and *Brucella* spp. [20, 21]. However, the  
60 incubation time should be increased for slow growing organisms such as fungi and *Mycobacteria* spp.; the  
61 latter being grown in vials containing Middlebrook 7H9. Modern laboratories rely on automated incubators  
62 (Table 1) including continuous monitoring for positive vials detection which significantly reduces the  
63 incubation time and the contamination rate. Blood culture positivity is generally detected by following CO<sub>2</sub>  
64 production by growing microorganisms that trigger a pH increase visualised by colour changes,  
65 fluorescence signal or red-ox variations.

## 66 **Interpretation of positive blood-cultures: contamination *versus* bloodstream** 67 **infection**

68 Contamination that represents up to 1/3 of positive blood cultures can occur when microbes not present in  
69 the bloodstream are introduced in the vial during the blood sampling [22]. Even if blood cultures are drawn  
70 under aseptic conditions, contaminations are often due to organisms of the skin flora such as coagulase  
71 negative staphylococci (CoNS), the 3<sup>rd</sup> most prevalent microbe identified in positive blood cultures (Figure  
72 1), or to organisms from the environment with low or absence of virulence towards humans such as  
73 *Micrococcus* spp., *Propionibacterium acnes*, most *Bacillus* spp. and most *Corynebacterium* spp. [22].  
74 Moreover, an inadequate blood volume increases the rate of contamination. Interestingly, peripheral  
75 venipuncture, arterial access or central venous accesses are associated with different contamination rates of  
76 36%, 10% and 7% respectively [22]. For venipuncture a promising approach to reduce to less than 30% the  
77 contamination rate is named the initial specimen diversion technique (ISDT), in which the first blood  
78 milliliter potentially containing bacteria not killed by skin surface antiseptics is discarded or used for other  
79 purposes [23, 24]. Nevertheless the specificity of blood culture for the diagnosis of BSI remains high as

80 most of the top microbes recovered from positive blood cultures are primarily pathogens such as  
81 *Escherichia coli*, *Staphylococcus aureus* or *Pseudomonas aeruginosa* respectively 2<sup>nd</sup>, 4<sup>th</sup> and 5<sup>th</sup> position  
82 (Table 1).

83 Together with the clinical signs and symptoms, several parameters can help to precise the significance of  
84 positive blood cultures: 1) the number of positive vials, the number of positive blood culture pairs as well  
85 as the proportion of positive cultures [25], 2) the site of sampling - catheter *versus* venous puncture - and  
86 3) the time to positivity, including the differential time to positivity between pairs collected from different  
87 sampling sites [26]. For this reason, international guidelines recommend drawing several set of blood vials  
88 [27]. Increasing the number of blood cultures increases the sensitivity due to the increased total volume  
89 collected [28]. Blood culture sampling should be repeated since bacteremia often occurs in intermittence.  
90 This is not the case of endocarditis or septic thrombophlebitis, where all the bottles are generally positive  
91 with pyogenic bacteria such as *S. aureus* and *S. pyogenes*.

92 When contamination is excluded, the organism detected and identified in the blood culture is likely present  
93 in the bloodstream at the time of sampling, which defines a bacteremia (or fungemia). Bacteremia or  
94 fungemia can be transient or sustained. Transient bacteremia correspond to a single episode of positive  
95 blood cultures due to the presence of microorganism during a short time-lapse in the bloodstream (less than  
96 30 min). They are generally caused by the manipulation of contaminated mucosa or invasive respiratory,  
97 gastro-intestinal or urogenital acts [29]. Conversely, multiple positive vials drawn at different time is  
98 synonymous of sustained bacteremia (fungemia). Sustained positive blood cultures are encountered in  
99 presence of endovascular infections such as endocarditis. In such cases a high number of blood cultures  
100 become positive without any difference in the time to positivity for bottles drawn simultaneously from  
101 different sites. In contrast a catheter infection is suspected when blood cultures drawn from a catheter  
102 become positive more than 2 hours before blood culture drawn from a venipuncture. This time to positivity  
103 difference exhibits an overall sensitivity of 91% and a specificity of 94% for the diagnosis of catheter  
104 infection [30]. The catheter can be removed and cultured by plating the catheter tip using the Maki roll-on  
105 semi-quantitative method [31]. Sustained bacteremia should be differentiated from persistent bacteremia

106 that is defined by the persistence of positive blood cultures despite the introduction of an anti-infectious  
107 treatment. Persistent bacteremia (fungemia) are generally due to organisms resistant to the prescribed  
108 antibiotic, to the presence of a second organism or to antibiotic inaccessibility to the site of infection (e.g.  
109 septic thrombosis).

## 110 **Identification and antibiotic susceptibility testing from positive blood culture**

111 Upon blood culture positivity, the first step is to perform a Gram staining with a blood culture aliquot. This  
112 is a mandatory analysis to confirm the presence of bacteria/fungi in the blood vial. If microbes are present,  
113 the morphotype provides a first hint on the etiology of the infection. Then microbes identification can be  
114 achieved: 1) starting from a subculture, 2) directly from the positive blood culture using nucleic acid-based  
115 methods such as hybridization and microarray or, 3) after a bacterial enrichment and purification step to  
116 obtain a “bacterial pellet”, suitable for a variety of approaches including matrix-assisted laser desorption  
117 ionization time-of-flight mass spectrometry (MALDI-TOF MS) (Figure 2).

## 118 **Identification approaches requiring a pure subculture**

119 After the Gram staining examination, the positive blood culture can be plated to insure pure culture (isolated  
120 colonies) that can be analyzed using conventional biochemical methods, MALDI-TOF MS and/or nucleic-  
121 acid based methods such as PCR and gene sequencing (Figure 2). A 12 to 24h incubation period is generally  
122 required to obtain enough isolated colonies for biochemical characterization whereas relatively short  
123 incubation (<6 hours) are often long enough for MALDI-TOF MS identification, the current best method  
124 for rapid bacterial identification. AST performed directly from a positive blood vial without a pellet  
125 preparation or a subculture is not recommended. Different AST methods can be applied from isolated  
126 colonies. Automated methods such as Vitek (BioMerieux) allow the testing of a high number of molecules  
127 at the same time. The interpretation of the result is automated and internal expert systems are able to detect

128 specific resistance mechanisms such as ESBL and carbapenemases. However, they do not give an exact  
129 MIC in contrast to E-test.

### 130 **Nucleic-acid based methods that can be used directly on positive blood cultures**

131 Molecular methods are generally faster than phenotypic approaches because they are culture independent.  
132 However, the use amplification-based nucleic acid methods such as PCR have to face several limitations  
133 associated with a blood sample: 1) presence of PCR inhibitors 2) presence of a high quantity of non-  
134 microbial nucleic acids 3) presence of contaminant DNA and 4) persistence of DNA from dead microbes  
135 (Opota et al 2015 on the same issue). Probes hybridization and microarrays that are non amplification-based  
136 nucleic acid methods are less influenced by inhibitors and less prone to contamination but they require a  
137 high bacterial or fungal load. Hence these methods are used downstream positive blood cultures in which  
138 the bacterial load can reaches  $1.10^6$  to  $2.10^8$  for Gram-positive cocci and  $2.10^7$  to  $1.10^9$  for Gram-negative  
139 bacilli (Figure 2) [32, 33] (Opota et al 2015 on the same issue).

140 Fluorescent in situ hybridization (FISH) that consists in the specific binding of fluorescent nucleic acid  
141 probes on complementary pathogens DNA sequences - 16S rRNA for bacteria and 18S rRNA for fungi -  
142 can be performed directly from the positive blood culture. The specific binding is observed using a  
143 fluorescent microscope. The choice of the probe is dependent on the Gram staining: staphylococci probes  
144 (*S. aureus*/CoNS), enterococci probes (*E. faecalis*/*E. faecium*), Gram negative probes (*E. coli*/*P.*  
145 *aeruginosa*/*K. pneumoniae*), yeast probes (*C. albicans*/*C. glabrata*/*C. parapsilosis*/*C. krusei*) for instance.  
146 The commercial solutions PNA-FISH and Quick-FISH (AdvanDx, USA) display a time to result of about  
147 1.5 to 3 hours with a sensitivity and specificity of 97-100 % and 90-100 % respectively (Table 2)[34-39].  
148 The AccuProbe system (Gen-Probe, San Diego, California) is based on DNA probe that can detect *S aureus*,  
149 *Streptococcus pneumoniae*, *Enterococci* spp., and group A and B streptococci . The sensistivity and  
150 specificity are above 97% at the exception of the *S. aureus* probes that demonstrate a sensitivity of 99.8%  
151 and a specificity of 80.8% [40, 41].



152 Microarrays allow the detection of a limited number of species which cover 90 to 95% of all the pathogens  
153 causing BSI. The turn-around time is about 2.5 to 4 hours with sensitivity ranging from 10 to 10<sup>5</sup> CFU/ml  
154 [42]. In contrast to FISH, microarrays generally contain probes for the detection of resistance genes such  
155 as *mecA*, *vanA/vanB* and *bla<sub>KPC</sub>*. For example, the Verigene system (Nanosphere, Northbrook, IL, USA)  
156 consists in two distinct kits for the detection of 12 Gram positive and 9 Gram negative bacterial species  
157 with a sensitivity ranging from 81 to 100% and a specificity higher than 98% [43, 44]. The Prove-it Sepsis  
158 assay (Mobidiag, Finland) combine a PCR with a microarray for a turnaround time of 3.5 hours, 95% of  
159 sensitivity and 99% of specificity (Table 2) [45].

160 POCT-PCR systems that allow the detection and identification of methicillin sensitive *Staphylococcus*  
161 *aureus* (MSSA) and methicillin resistant *Staphylococcus aureus* (MRSA) have been dedicated to blood  
162 cultures because of the clinical impact and the epidemiological concern of this pathogen [46, 47].  
163 MSSA/MRSA detection POCT such as, GeneXpert MRSA/SA BC Assay (Cepheid, Sunnyvale, CA) [48,  
164 49] and the StaphSR assay (BD GeneOhm, San Diego, CA) [50, 51] are based on multiplex real-time PCR  
165 to detect *S. aureus* and the presence of the *mecA* gene. The results are obtained in approximately 1.5 h. The  
166 FilmArray (Idaho Technology, Salt Lake City, UT, USA) is a multiplex PCR-based system designed to  
167 detect 25 microbes (90 to 95% of the pathogens involved in blood cultures) and the resistance genes *mecA*,  
168 *vanA* and *vanB* and *bla<sub>KPC</sub>* [52].

## 169 **Subculture independent approaches: identification and antibiotic susceptibility** 170 **testing using a blood-culture microbial pellet.**

171 The use of matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS)  
172 technology for the identification of microorganisms is among the major revolution in clinical microbiology  
173 laboratory of the last years. Microbial identification using MALDI-TOF MS is based on the comparison of  
174 a protein profile obtained by mass-spectrometry from a bacterial or fungal sample with a database of profile  
175 obtained from characterized microbes [53, 54]. MALDI-TOF MS is an accurate and fast approach, which

176 performance largely depends on microorganism's purity and quantity. Therefore, bacterial enrichment and  
177 purification procedures are required from positive blood cultures which contain high concentration of non  
178 microbial material that may interfere with MALDI-TOF MS identification and AST. Several in-house and  
179 commercial methods have been developed to isolate and concentrate microorganisms from positive blood  
180 cultures including lysis centrifugation methods [55-57], saponin or equivalent mild detergent methods [58,  
181 59], serum separator method [60] and the commercial MALDI Sepsityper Kit (Bruker Daltonics Inc.,  
182 Billerica, MA) [61]. These pellet preparation protocols may not only be used for MALDI-TOF MS  
183 identification but also provide enough starting material for other downstream applications including Gram  
184 staining, AST [62] and POCT PCR [49].

### 185 **MALDI-TOF MS on positive blood-culture pellet**

186 The main MALDI-TOF MS systems commercially available, the Autoflex II mass spectrometer (Bruker  
187 Daltonik) and Axima Assurance system (Shimadzu Corporation) display similar performances [53, 54, 63,  
188 64]. The performances of MALDI-TOF MS identification vary according to the enrichment and purification  
189 method (Table 2). In the study performed by Prod'hom et al., a 78.7% correct identification by MALDI-  
190 TOF MS was obtained from blood culture pellets. Among samples giving no reliable identification by  
191 MALDI-TOF MS, 81% were blood culture positive for gram positive bacteria including mainly  
192 streptococci and coagulase-negative staphylococci [55]. Using a differential centrifugation protocol,  
193 March-Rossello et al. correctly identified 97.3% of Gram negative bacteria and 98.4% of Gram-positive  
194 bacteria [65]. Poor MALDI-TOF MS identifications from blood culture preparation are mainly observed  
195 with difficult-to-lyse bacteria (e.g. *Klebsiella pneumoniae*), closely related bacterial species (e.g  
196 *Streptococcus mitis* group) and bacteria such as anaerobes that are poorly represented in the MALDI-TOF  
197 MS database [53].

### 198 **Antibiotic susceptibility testing (AST) on positive blood-culture pellet**

199 Automated microbial systems cards and manual disk diffusion assays were directly used to perform AST  
200 from purified and/or enriched microbial samples obtained from positive blood culture. Machen *et al.*

201 performed a same day AST by directly inoculating the AST automated microbial system (VITEK 2) with  
202 filtered microorganisms from positive blood cultures. A 93.5 % category agreement with tested antibiotics  
203 was obtained with only 1.7 % major error (ME) and 1.3 % very major error (VME) according to definitions  
204 given by the FDA for interpretive agreement results [66]. Similar results were observed when the VITEK  
205 2 was inoculated with bacterial pellets obtained by ammonium chloride lysis centrifugation [62] or when  
206 the BD Phoenix (BD Diagnostics) system was inoculated with bacteria harvested using serum separator  
207 tubes [67]. However, some antibiotics known to present frequent discrepancies compared to conventional  
208 approaches need to be confirmed by disk diffusion assays and/or E-test directly performed from the same  
209 blood culture bacterial preparations [62].

210 The emergence of broad spectrum antibiotic resistance mechanisms triggered the development of methods  
211 allowing rapid detection of ESBL and Carbapenemase activities on blood cultures positive for Gram  
212 negative bacteria. Using a Triton lysis-centrifugation method, ESBL activities can be directly and rapidly  
213 (less than 1 hour) detected from spiked blood culture using the ESBL NP test with 100% sensitivity and  
214 specificity [68]. Interestingly, the ESBL NP test applied on blood culture pellets showed a higher  
215 performance compared to the same test performed on bacteria grown on agar plates which exhibited a 100%  
216 specificity; the decreased sensitivity (92.6%) is due to the poor performance of the test (25% sensitivity)  
217 for the detection of non-CTX-M ESBLs producers. The higher performance observed with this test applied  
218 on blood culture samples is likely explained by the very high bacterial inoculum recovered from positive  
219 blood culture. Another approach to detect ESBLs from positive blood cultures is the chromogenic  
220 cephalosporin HMRZ-86  $\beta$ LACTA test (BioRad) exhibiting a 100% sensitivity and specificity following a  
221 2 hours subculture in tryptone soya broth (TSB) to prevent inhibition of the test by lysed blood [69]. Thus  
222 in Lausanne, we applied it on purified bacterial pellets with accurate results (Prod'hom *et al.* submitted).  
223 The detection of carbapenemase activity from positive blood cultures can be performed with the Carba NP  
224 with 97.9 % sensitivity and 100% specificity test following a 3 hours selective enrichment in brain-heart  
225 infusion (BHI) containing imipenem [70]. A lower detection sensitivity (91.3%) was observed with OXA-  
226 48 producers whereas 100% of sensitivity was obtained with other classes of carbapenemases.

## 227 **POCT PCR on positive blood-culture pellet**

228 Rapid PCR-based test such as the GeneXpert MRSA/SA BC Assay (Cepheid, Sunnyvale, CA) can be  
229 applied on both native and microbial purified and enriched fraction of positive blood cultures (Figure 2).  
230 The GeneXpert MRSA/SA test was applied on *Staphylococcus aureus* blood culture bacterial pellets  
231 identified by MALDI-TOF MS and showed 99% of sensitivity and 100% of specificity, allowing a  
232 significant reduction of anti-MRSA antibiotics misuse from 26.1% to 8.1% [49].

233

## 234 **Conclusions**

235 New technologies and new methods for the diagnostic of positive blood cultures allow a significant  
236 reduction of the TAT for both identification and AST, with a positive impact on the management of patients  
237 suffering from bloodstream infections.

238 Some of these approaches such as microbial enrichment via centrifugation require significant hands on time  
239 and experienced lab technician, which may hinder their implementation in laboratories that process large  
240 volumes of positive blood cultures and/or that have limited human resources. Thus, the emergence of new  
241 laboratory methodologies and new laboratory automated technologies, should help the implementation of  
242 these new diagnostic approaches.

243 The example of recent development for the diagnosis of bloodstream infections highlight the importance  
244 of a dynamic R&D process in diagnostic laboratories that promote innovation and implementation of the  
245 most recent technologies for the benefit of patients care, while keeping an acceptable cost per test ratio.

## 246 **Transparency declaration**

247 No conflict of interest declared.

## 248 Acknowledgements

249 We thank the technicians of the diagnostic laboratory of the Institute of Microbiology, of the University  
250 Hospital Center of Lausanne for their help to implement or to test in the laboratory some of the technologies  
251 reviewed herein.

## 252 References

- 253 1 Ferrer R, Martin-Loeches I, Phillips G, et al. Empiric antibiotic treatment reduces mortality in  
254 severe sepsis and septic shock from the first hour: Results from a guideline-based performance  
255 improvement program\*. *Critical care medicine*. 2014; **42**: 1749-1755.
- 256 2 Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: International guidelines for  
257 management of severe sepsis and septic shock: 2012. *Critical care medicine*. 2013; **41**: 580-637.
- 258 3 Levy MM, Artigas A, Phillips GS, et al. Outcomes of the surviving sepsis campaign in intensive  
259 care units in the USA and europe: A prospective cohort study. *The Lancet infectious diseases*. 2012;  
260 **12**: 919-924.
- 261 4 Marshall JC, Dellinger RP, Levy M. The surviving sepsis campaign: A history and a perspective.  
262 *Surgical infections*. 2010; **11**: 275-281.
- 263 5 Levy MM, Dellinger RP, Townsend SR, et al. The surviving sepsis campaign: Results of an  
264 international guideline-based performance improvement program targeting severe sepsis. *Critical*  
265 *care medicine*. 2010; **38**: 367-374.
- 266 6 Huang L, Zhang YY, Sun LY. Time to positivity of blood culture can predict different candida  
267 species instead of pathogen concentration in candidemia. *European journal of clinical*  
268 *microbiology & infectious diseases : official publication of the European Society of Clinical*  
269 *Microbiology*. 2013; **32**: 917-922.
- 270 7 Taur Y, Cohen N, Dubnow S, Paskovaty A, Seo SK. Effect of antifungal therapy timing on  
271 mortality in cancer patients with candidemia. *Antimicrobial agents and chemotherapy*. 2010; **54**:  
272 184-190.
- 273 8 Chaubey VP, Pitout JD, Dalton B, et al. Clinical outcome of empiric antimicrobial therapy of  
274 bacteremia due to extended-spectrum beta-lactamase producing escherichia coli and klebsiella  
275 pneumoniae. *BMC research notes*. 2010; **3**: 116.
- 276 9 Paul M, Shani V, Muchtar E, Kariv G, Robenshtok E, Leibovici L. Systematic review and meta-  
277 analysis of the efficacy of appropriate empiric antibiotic therapy for sepsis. *Antimicrobial agents*  
278 *and chemotherapy*. 2010; **54**: 4851-4863.
- 279 10 Zaragoza R, Artero A, Camarena JJ, Sancho S, Gonzalez R, Nogueira JM. The influence of  
280 inadequate empirical antimicrobial treatment on patients with bloodstream infections in an  
281 intensive care unit. *Clinical microbiology and infection : the official publication of the European*  
282 *Society of Clinical Microbiology and Infectious Diseases*. 2003; **9**: 412-418.
- 283 11 Wain J, Diep TS, Ho VA, et al. Quantitation of bacteria in blood of typhoid fever patients and  
284 relationship between counts and clinical features, transmissibility, and antibiotic resistance.  
285 *Journal of clinical microbiology*. 1998; **36**: 1683-1687.
- 286 12 Henry NK, McLimans CA, Wright AJ, Thompson RL, Wilson WR, Washington JA, 2nd.  
287 Microbiological and clinical evaluation of the isolator lysis-centrifugation blood culture tube.  
288 *Journal of clinical microbiology*. 1983; **17**: 864-869.

289 13 Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. Iii. Reassessment of  
290 etiology, epidemiology and ecology in 612 patients. *The American journal of medicine*. 1980; **68**:  
291 332-343.

292 14 Werner AS, Cobbs CG, Kaye D, Hook EW. Studies on the bacteremia of bacterial endocarditis.  
293 *JAMA : the journal of the American Medical Association*. 1967; **202**: 199-203.

294 15 Bacconi A, Richmond GS, Baroldi MA, et al. Improved sensitivity for molecular detection of  
295 bacteria and candida in blood. *Journal of clinical microbiology*. 2014.

296 16 Cockerill FR, 3rd, Wilson JW, Vetter EA, et al. Optimal testing parameters for blood cultures.  
297 *Clinical infectious diseases : an official publication of the Infectious Diseases Society of America*.  
298 2004; **38**: 1724-1730.

299 17 Riedel S, Bourbeau P, Swartz B, et al. Timing of specimen collection for blood cultures from febrile  
300 patients with bacteremia. *Journal of clinical microbiology*. 2008; **46**: 1381-1385.

301 18 Dellinger RP, Levy MM, Carlet JM, et al. Surviving sepsis campaign: International guidelines for  
302 management of severe sepsis and septic shock: 2008. *Intensive care medicine*. 2008; **34**: 17-60.

303 19 Fenollar F, Raoult D. Molecular diagnosis of bloodstream infections caused by non-cultivable  
304 bacteria. *International journal of antimicrobial agents*. 2007; **30 Suppl 1**: S7-15.

305 20 Baron EJ, Scott JD, Tompkins LS. Prolonged incubation and extensive subculturing do not increase  
306 recovery of clinically significant microorganisms from standard automated blood cultures. *Clinical*  
307 *infectious diseases : an official publication of the Infectious Diseases Society of America*. 2005; **41**:  
308 1677-1680.

309 21 Petti CA, Bhally HS, Weinstein MP, et al. Utility of extended blood culture incubation for isolation  
310 of haemophilus, actinobacillus, cardiobacterium, eikenella, and kingella organisms: A retrospective  
311 multicenter evaluation. *Journal of clinical microbiology*. 2006; **44**: 257-259.

312 22 Gonsalves WI, Cornish N, Moore M, Chen A, Varman M. Effects of volume and site of blood draw  
313 on blood culture results. *Journal of clinical microbiology*. 2009; **47**: 3482-3485.

314 23 Binkhamis K, Forward K. Effect of the initial specimen diversion technique on blood culture  
315 contamination rates. *Journal of clinical microbiology*. 2014; **52**: 980-981.

316 24 Patton RG, Schmitt T. Innovation for reducing blood culture contamination: Initial specimen  
317 diversion technique. *Journal of clinical microbiology*. 2010; **48**: 4501-4503.

318 25 Hall KK, Lyman JA. Updated review of blood culture contamination. *Clinical microbiology*  
319 *reviews*. 2006; **19**: 788-802.

320 26 Kassis C, Rangaraj G, Jiang Y, Hachem RY, Raad I. Differentiating culture samples representing  
321 coagulase-negative staphylococcal bacteremia from those representing contamination by use of  
322 time-to-positivity and quantitative blood culture methods. *Journal of clinical microbiology*. 2009;  
323 **47**: 3255-3260.

324 27 Lee A, Mirrett S, Reller LB, Weinstein MP. Detection of bloodstream infections in adults: How  
325 many blood cultures are needed? *Journal of clinical microbiology*. 2007; **45**: 3546-3548.

326 28 Li J, Plorde JJ, Carlson LG. Effects of volume and periodicity on blood cultures. *Journal of clinical*  
327 *microbiology*. 1994; **32**: 2829-2831.

328 29 Laupland KB, Church DL. Population-based epidemiology and microbiology of community-onset  
329 bloodstream infections. *Clinical microbiology reviews*. 2014; **27**: 647-664.

330 30 Blot F, Schmidt E, Nitenberg G, et al. Earlier positivity of central-venous- versus peripheral-blood  
331 cultures is highly predictive of catheter-related sepsis. *Journal of clinical microbiology*. 1998; **36**:  
332 105-109.

333 31 Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-  
334 catheter-related infection. *The New England journal of medicine*. 1977; **296**: 1305-1309.

335 32 Christner M, Rohde H, Wolters M, Sobottka I, Wegscheider K, Aepfelbacher M. Rapid  
336 identification of bacteria from positive blood culture bottles by use of matrix-assisted laser  
337 desorption-ionization time of flight mass spectrometry fingerprinting. *Journal of clinical*  
338 *microbiology*. 2010; **48**: 1584-1591.

339 33 Tan TY, Ng LS, Kwang LL. Evaluation of disc susceptibility tests performed directly from positive  
340 blood cultures. *Journal of clinical pathology*. 2008; **61**: 343-346.

341 34 Deck MK, Anderson ES, Buckner RJ, et al. Multicenter evaluation of the staphylococcus quickfish  
342 method for simultaneous identification of staphylococcus aureus and coagulase-negative  
343 staphylococci directly from blood culture bottles in less than 30 minutes. *Journal of clinical  
344 microbiology*. 2012; **50**: 1994-1998.

345 35 Martinez RM, Bauerle ER, Fang FC, Butler-Wu SM. Evaluation of three rapid diagnostic methods  
346 for direct identification of microorganisms in positive blood cultures. *Journal of clinical  
347 microbiology*. 2014; **52**: 2521-2529.

348 36 Farina C, Perin S, Andreoni S, et al. Evaluation of the peptide nucleic acid fluorescence in situ  
349 hybridisation technology for yeast identification directly from positive blood cultures: An Italian  
350 experience. *Mycoses*. 2012; **55**: 388-392.

351 37 Carretto E, Bardaro M, Russello G, Mirra M, Zuelli C, Barbarini D. Comparison of the  
352 staphylococcus quickfish bc test with the tube coagulase test performed on positive blood cultures  
353 for evaluation and application in a clinical routine setting. *Journal of clinical microbiology*. 2013;  
354 **51**: 131-135.

355 38 Forrest GN. Pna fish: Present and future impact on patient management. *Expert review of molecular  
356 diagnostics*. 2007; **7**: 231-236.

357 39 Wagner J, Schilcher G, Zollner-Schwetz I, et al. Microbiological screening for earlier detection of  
358 central venous catheter-related bloodstream infections. *European journal of clinical investigation*.  
359 2013; **43**: 964-969.

360 40 Arbique JC, Poyart C, Trieu-Cuot P, et al. Accuracy of phenotypic and genotypic testing for  
361 identification of streptococcus pneumoniae and description of streptococcus pseudopneumoniae sp.  
362 Nov. *Journal of clinical microbiology*. 2004; **42**: 4686-4696.

363 41 Lindholm L, Sarkkinen H. Direct identification of gram-positive cocci from routine blood cultures  
364 by using accuprobe tests. *Journal of clinical microbiology*. 2004; **42**: 5609-5613.

365 42 Wiesinger-Mayr H, Vierlinger K, Pichler R, et al. Identification of human pathogens isolated from  
366 blood using microarray hybridisation and signal pattern recognition. *BMC microbiology*. 2007; **7**:  
367 78.

368 43 Mancini N, Infurnari L, Ghidoli N, et al. Potential impact of a microarray-based nucleic acid assay  
369 for rapid detection of gram-negative bacteria and resistance markers in positive blood cultures.  
370 *Journal of clinical microbiology*. 2014; **52**: 1242-1245.

371 44 Wojewoda CM, Sercia L, Navas M, et al. Evaluation of the verigene gram-positive blood culture  
372 nucleic acid test for rapid detection of bacteria and resistance determinants. *Journal of clinical  
373 microbiology*. 2013; **51**: 2072-2076.

374 45 Tissari P, Zumla A, Tarkka E, et al. Accurate and rapid identification of bacterial species from  
375 positive blood cultures with a DNA-based microarray platform: An observational study. *Lancet*.  
376 2010; **375**: 224-230.

377 46 Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison  
378 of mortality associated with methicillin-resistant and methicillin-susceptible staphylococcus aureus  
379 bacteremia: A meta-analysis. *Clinical infectious diseases : an official publication of the Infectious  
380 Diseases Society of America*. 2003; **36**: 53-59.

381 47 Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial  
382 bloodstream infections in us hospitals: Analysis of 24,179 cases from a prospective nationwide  
383 surveillance study. *Clinical infectious diseases : an official publication of the Infectious Diseases  
384 Society of America*. 2004; **39**: 309-317.

385 48 Spencer DH, Sellenriek P, Burnham CA. Validation and implementation of the genexpert mrsa/sa  
386 blood culture assay in a pediatric setting. *American journal of clinical pathology*. 2011; **136**: 690-  
387 694.

388 49 Clerc O, Prod'hom G, Senn L, et al. Matrix-assisted laser desorption ionization time-of-flight mass  
389 spectrometry and pcr-based rapid diagnosis of staphylococcus aureus bacteraemia. *Clinical*

390 *microbiology and infection : the official publication of the European Society of Clinical*  
391 *Microbiology and Infectious Diseases*. 2014; **20**: 355-360.

392 50 Stamper PD, Cai M, Howard T, Speser S, Carroll KC. Clinical validation of the molecular bd  
393 geneohm staphsr assay for direct detection of staphylococcus aureus and methicillin-resistant  
394 staphylococcus aureus in positive blood cultures. *Journal of clinical microbiology*. 2007; **45**: 2191-  
395 2196.

396 51 Ishikawa H, Kutsukake E, Chiba K, Fukui T, Matsumoto T. The performance of the bd geneohm  
397 mrsa assay for mrsa isolated from clinical patients in japan, including the effects of specimen  
398 contamination and ways to improve it. *Journal of infection and chemotherapy : official journal of*  
399 *the Japan Society of Chemotherapy*. 2011; **17**: 214-218.

400 52 Blaschke AJ, Heyrend C, Byington CL, et al. Rapid identification of pathogens from positive blood  
401 cultures by multiplex polymerase chain reaction using the filmarray system. *Diagnostic*  
402 *microbiology and infectious disease*. 2012; **74**: 349-355.

403 53 Croxatto A, Prod'hom G, Greub G. Applications of maldi-tof mass spectrometry in clinical  
404 diagnostic microbiology. *FEMS microbiology reviews*. 2012; **36**: 380-407.

405 54 Seng P, Drancourt M, Gouriet F, et al. Ongoing revolution in bacteriology: Routine identification  
406 of bacteria by matrix-assisted laser desorption ionization time-of-flight mass spectrometry. *Clinical*  
407 *infectious diseases : an official publication of the Infectious Diseases Society of America*. 2009; **49**:  
408 543-551.

409 55 Prod'hom G, Bizzini A, Durussel C, Bille J, Greub G. Matrix-assisted laser desorption ionization-  
410 time of flight mass spectrometry for direct bacterial identification from positive blood culture  
411 pellets. *Journal of clinical microbiology*. 2010; **48**: 1481-1483.

412 56 Stevenson LG, Drake SK, Murray PR. Rapid identification of bacteria in positive blood culture  
413 broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Journal of*  
414 *clinical microbiology*. 2010; **48**: 444-447.

415 57 Croxatto A, Prod'hom G, Durussel C, Greub G. Preparation of a blood culture pellet for rapid  
416 bacterial identification and antibiotic susceptibility testing. *Journal of visualized experiments :*  
417 *JoVE*. 2014.

418 58 Gray TJ, Thomas L, Olma T, Iredell JR, Chen SC. Rapid identification of gram-negative organisms  
419 from blood culture bottles using a modified extraction method and maldi-tof mass spectrometry.  
420 *Diagnostic microbiology and infectious disease*. 2013; **77**: 110-112.

421 59 Meex C, Neuville F, Descy J, et al. Direct identification of bacteria from bact/alert anaerobic  
422 positive blood cultures by maldi-tof ms: Maldi sepsityper kit versus an in-house saponin method  
423 for bacterial extraction. *Journal of medical microbiology*. 2012; **61**: 1511-1516.

424 60 Moussaoui W, Jaulhac B, Hoffmann AM, et al. Matrix-assisted laser desorption ionization time-  
425 of-flight mass spectrometry identifies 90% of bacteria directly from blood culture vials. *Clinical*  
426 *microbiology and infection : the official publication of the European Society of Clinical*  
427 *Microbiology and Infectious Diseases*. 2010; **16**: 1631-1638.

428 61 Kok J, Thomas LC, Olma T, Chen SC, Iredell JR. Identification of bacteria in blood culture broths  
429 using matrix-assisted laser desorption-ionization sepsityper and time of flight mass spectrometry.  
430 *PloS one*. 2011; **6**: e23285.

431 62 Prod'hom G, Durussel C, Greub G. A simple blood-culture bacterial pellet preparation for faster  
432 accurate direct bacterial identification and antibiotic susceptibility testing with the vitek 2 system.  
433 *Journal of medical microbiology*. 2013; **62**: 773-777.

434 63 Cherkaoui A, Hibbs J, Emonet S, et al. Comparison of two matrix-assisted laser desorption  
435 ionization-time of flight mass spectrometry methods with conventional phenotypic identification  
436 for routine identification of bacteria to the species level. *Journal of clinical microbiology*. 2010;  
437 **48**: 1169-1175.

438 64 Mellmann A, Bimet F, Bizet C, et al. High interlaboratory reproducibility of matrix-assisted laser  
439 desorption ionization-time of flight mass spectrometry-based species identification of  
440 nonfermenting bacteria. *Journal of clinical microbiology*. 2009; **47**: 3732-3734.



441 65 March-Rossello GA, Munoz-Moreno MF, Garcia-Loygorri-Jordan de Urries MC, Bratos-Perez  
442 MA. A differential centrifugation protocol and validation criterion for enhancing mass  
443 spectrometry (maldi-tof) results in microbial identification using blood culture growth bottles.  
444 *European journal of clinical microbiology & infectious diseases : official publication of the*  
445 *European Society of Clinical Microbiology*. 2013; **32**: 699-704.

446 66 Machen A, Drake T, Wang YF. Same day identification and full panel antimicrobial susceptibility  
447 testing of bacteria from positive blood culture bottles made possible by a combined lysis-filtration  
448 method with maldi-tof vitek mass spectrometry and the vitek2 system. *PLoS one*. 2014; **9**: e87870.

449 67 Beuvring J, van der Donk CF, Linssen CF, Wolffs PF, Verbon A. Evaluation of direct inoculation  
450 of the bd phoenix system from positive bactec blood cultures for both gram-positive cocci and  
451 gram-negative rods. *BMC microbiology*. 2011; **11**: 156.

452 68 Nordmann P, Dortet L, Poirel L. Rapid detection of extended-spectrum-beta-lactamase-producing  
453 enterobacteriaceae. *Journal of clinical microbiology*. 2012; **50**: 3016-3022.

454 69 Jain S, Andrews J, Fraise A, Brenwald N. Rapid detection of extended-spectrum beta-lactamase-  
455 producing gram-negative bacilli in blood cultures. *The Journal of antimicrobial chemotherapy*.  
456 2007; **60**: 652-654.

457 70 Dortet L, Brechard L, Poirel L, Nordmann P. Rapid detection of carbapenemase-producing  
458 enterobacteriaceae from blood cultures. *Clinical microbiology and infection : the official*  
459 *publication of the European Society of Clinical Microbiology and Infectious Diseases*. 2014; **20**:  
460 340-344.

461 71 Morgan MA, Marlowe E, Novak-Weekly S, et al. A 1.5 hour procedure for identification of  
462 enterococcus species directly from blood cultures. *Journal of visualized experiments : JoVE*. 2011.

463 72 Hensley DM, Tapia R, Encina Y. An evaluation of the advandx staphylococcus aureus/cns pna fish  
464 assay. *Clinical laboratory science : journal of the American Society for Medical Technology*. 2009;  
465 **22**: 30-33.

466 73 Sogaard M, Hansen DS, Fiandaca MJ, Stender H, Schonheyder HC. Peptide nucleic acid  
467 fluorescence in situ hybridization for rapid detection of klebsiella pneumoniae from positive blood  
468 cultures. *Journal of medical microbiology*. 2007; **56**: 914-917.

469 74 Harris DM, Hata DJ. Rapid identification of bacteria and candida using pna-fish from blood and  
470 peritoneal fluid cultures: A retrospective clinical study. *Annals of clinical microbiology and*  
471 *antimicrobials*. 2013; **12**: 2.

472 75 Stone NR, Gorton RL, Barker K, Ramnarain P, Kibbler CC. Evaluation of pna-fish yeast traffic  
473 light for rapid identification of yeast directly from positive blood cultures and assessment of clinical  
474 impact. *Journal of clinical microbiology*. 2013; **51**: 1301-1302.

475 76 Deck MK, Anderson ES, Buckner RJ, et al. Rapid detection of enterococcus spp. Direct from blood  
476 culture bottles using enterococcus quickfish method: A multicenter investigation. *Diagnostic*  
477 *microbiology and infectious disease*. 2014; **78**: 338-342.

478 77 Alby K, Daniels LM, Weber DJ, Miller MB. Development of a treatment algorithm for streptococci  
479 and enterococci from positive blood cultures identified with the verigene gram-positive blood  
480 culture assay. *Journal of clinical microbiology*. 2013; **51**: 3869-3871.

481 78 Beal SG, Ciorca J, Smith G, et al. Evaluation of the nanosphere verigene gram-positive blood  
482 culture assay with the versatrek blood culture system and assessment of possible impact on selected  
483 patients. *Journal of clinical microbiology*. 2013; **51**: 3988-3992.

484 79 Buchan BW, Ginocchio CC, Manii R, et al. Multiplex identification of gram-positive bacteria and  
485 resistance determinants directly from positive blood culture broths: Evaluation of an automated  
486 microarray-based nucleic acid test. *PLoS medicine*. 2013; **10**: e1001478.

487 80 Sullivan KV, Turner NN, Roundtree SS, et al. Rapid detection of gram-positive organisms by use  
488 of the verigene gram-positive blood culture nucleic acid test and the bact/alert pediatric fan system  
489 in a multicenter pediatric evaluation. *Journal of clinical microbiology*. 2013; **51**: 3579-3584.

490 81 Bhatti MM, Boonlayangoor S, Beavis KG, Tesic V. Evaluation of filmarray and verigene systems  
491 in the rapid identification of positive blood cultures. *Journal of clinical microbiology*. 2014.

- 492 82 Dodemont M, De Mendonca R, Nonhoff C, Roisin S, Denis O. Performance of the verigene gram-  
493 negative blood culture assay for rapid detection of bacteria and resistance determinants. *Journal of*  
494 *clinical microbiology*. 2014; **52**: 3085-3087.
- 495 83 Mestas J, Polanco CM, Felsenstein S, Dien Bard J. Performance of the verigene gram-positive  
496 blood culture assay for direct detection of gram-positive organisms and resistance markers in a  
497 pediatric hospital. *Journal of clinical microbiology*. 2014; **52**: 283-287.
- 498 84 Tojo M, Fujita T, Ainoda Y, et al. Evaluation of an automated rapid diagnostic assay for detection  
499 of gram-negative bacteria and their drug-resistance genes in positive blood cultures. *PloS one*.  
500 2014; **9**: e94064.
- 501 85 Sullivan KV, Deburger B, Roundtree SS, Ventrola CA, Blecker-Shelly DL, Mortensen JE.  
502 Pediatric multicenter evaluation of the verigene gram-negative blood culture test for rapid detection  
503 of inpatient bacteremia involving gram-negative organisms, extended-spectrum beta-lactamases,  
504 and carbapenemases. *Journal of clinical microbiology*. 2014; **52**: 2416-2421.
- 505 86 Rand KH, Delano JP. Direct identification of bacteria in positive blood cultures: Comparison of  
506 two rapid methods, filmarray and mass spectrometry. *Diagnostic microbiology and infectious*  
507 *disease*. 2014; **79**: 293-297.
- 508 87 Paolucci M, Foschi C, Tamburini MV, Ambretti S, Lazzarotto T, Landini MP. Comparison between  
509 maldi-tof ms and filmarray blood culture identification panel for rapid identification of yeast from  
510 positive blood culture. *Journal of microbiological methods*. 2014; **104C**: 92-93.
- 511 88 Altun O, Almuhayawi M, Ullberg M, Ozenci V. Clinical evaluation of the filmarray blood culture  
512 identification panel in identification of bacteria and yeasts from positive blood culture bottles.  
513 *Journal of clinical microbiology*. 2013; **51**: 4130-4136.
- 514 89 Laudat P, Demondion E, Jouannet C, et al. [detection of staphylococcus aureus resistant to  
515 methicillin (mrsa) by molecular biology (cephid genexpert il, geneohm bd, roche lightcycler,  
516 hyplex evigene i2a) versus screening by culture: Economic and practical strategy for the  
517 laboratory]. *Pathologie-biologie*. 2012; **60**: 208-213.
- 518 90 Scanvic A, Courdavault L, Sollet JP, Le Turdu F. [interest of real-time pcr xpert mrsa/sa on  
519 genexpert((r)) dx system in the investigation of staphylococcal bacteremia]. *Pathologie-biologie*.  
520 2011; **59**: 67-72.
- 521 91 Davies J, Gordon CL, Tong SY, Baird RW, Davis JS. Impact of results of a rapid staphylococcus  
522 aureus diagnostic test on prescribing of antibiotics for patients with clustered gram-positive cocci  
523 in blood cultures. *Journal of clinical microbiology*. 2012; **50**: 2056-2058.
- 524 92 Grobner S, Dion M, Plante M, Kempf VA. Evaluation of the bd geneohm staphsr assay for detection  
525 of methicillin-resistant and methicillin-susceptible staphylococcus aureus isolates from spiked  
526 positive blood culture bottles. *Journal of clinical microbiology*. 2009; **47**: 1689-1694.
- 527 93 Kimura T, Komori T, Hirose Y, et al. [evaluation of the mrsa rapid detection assay (bd geneohm  
528 mrsa detection kit) by a real-time pcr]. *Rinsho byori The Japanese journal of clinical pathology*.  
529 2009; **57**: 425-430.
- 530 94 Tang YW, Kilic A, Yang Q, et al. Staphplex system for rapid and simultaneous identification of  
531 antibiotic resistance determinants and panton-valentine leukocidin detection of staphylococci from  
532 positive blood cultures. *Journal of clinical microbiology*. 2007; **45**: 1867-1873.

533


534

535

536 **Figure legends**

537


538 **Figure 1:** Top 20 of the microbes identified from positive BC during 1 year. Data from our 1000-bed  
539 tertiary care university hospital during the year 2013. The pie chart represents the distribution per  
540 morphotypes of all the microorganisms (total = 16682 identifications).



541

542

543 **Figure 2:** Methods to identify microorganisms from positive blood cultures. A) Directly from positive  
 544 blood culture, B) via a subculture step and C) using a purified bacterial.



545

546

547

**Table 1:** Main automated blood culture incubation systems currently commercially available.

System (Manufacturer)	Main blood culture media and characteristics	Positivity detection system
BD BACTEC (BD Diagnostics, Franklin Lakes, NJ, USA)	<ul style="list-style-type: none"> <li>- Standard aerobic and anaerobic broth media.</li> <li>- Media containing resin particles.</li> <li>-Media specifically designed for small blood volume inoculation.</li> <li>-Media containing a lysing agent to increase the recovery of organisms phagocytosed.</li> <li>-Media optimized for the growth of mycobacteria.</li> <li>- Specific algorithms for fastidious organisms (e.g <i>Haemophilus</i> spp and <i>Neisseria</i> spp.).</li> </ul>	fluorescent sensor of CO <sub>2</sub> production
BacT/ALERT 3D (bioMérieux, Durham, NC)	<ul style="list-style-type: none"> <li>-Plastic bottles.</li> <li>-Standard aerobic and anaerobic broth media.</li> <li>-Media containing activated charcoal particles*.</li> <li>-Media specifically designed for small blood volume inoculation.</li> <li>-Media supplemented with Middlebrook 7H9 for micobacteria growth.</li> <li>-Enriched media.</li> </ul>	colorimetric sensor of CO <sub>2</sub> production
VersaTREK, (TREK Diagnostic Systems, ThermoFisher Scientific, Waltham, MA)	<ul style="list-style-type: none"> <li>- Standard aerobic and anaerobic broth media for samples from 0.1 to10 ml, optimized to minimize the impact of antibiotics.</li> </ul>	Monitoring of red-ox variations

\* The presence of charcoal particles prevent the use of the pellet for direct identification from positive BC using MALDI-TOF MS

551 **Table 2:** Characteristics of the commercially available systems for the identification of microbes from

552 positive blood culture

553

554

System	Methods	Time to result	Microorganisms coverage	Resistance and virulence markers	Sensitivity Specificity Correlation with conventional methods (%)	Comments	References
<b>PNA FISH and QuickFISH</b> (AdvanDx, Wolburn, MA)	FISH	<1-3 hours	4 Gram positive 4 Gram negative 5 Fungi	0	97-100 90-100 96-99	+ : rapid, sensitive and specific - : dependent on the choice of the probes to be tested, no resistance marker	[34, 37, 38, 71-76]
<b>AccuProbe</b> (Gen-Probe, San Diego, CA, USA)	FISH	<1 hour	<i>S. aureus</i> <i>Enterococcus</i> spp. <i>S. pneumoniae</i> <i>Streptococcus</i> group A <i>Streptococcus</i> group B	0	80.8-100 98.7-100 nr	+ : high specificity - : variable sensitivity, no resistance marker, limited number of publications	[40, 41]
<b>Verigene</b> (Nanosphere, Northbrook, IL, USA)	Microarray	2.5 hours	12 Gram positive 9 Gram negative	<i>mecA</i> , <i>vanA/B</i> , KPC, NDM, CTX- M, VIM, IMP, OX A12	81-100 98-100 nr	+ : detection of resistance markers, good specificity - : variable sensitivity, narrow range of pathogens detected	[43, 77-85]
<b>Prove-it Sepsis</b> (Mobidiag, Finland)	Microarray	3.5 hours	60 bacteria 13 fungi	<i>mecA</i>	95 % 99 % nr	+ : sensitive and specific - : limited number of publications	[45]
<b>FilmArray</b> (Idaho Technology, Salt Lake City, UT, USA)	Multiplex PCR	1 hour	8 Gram positive 11 Gram negative 5 Fungi	<i>mecA</i> , <i>vanA/B</i> , KPC	97-95 91-98 nr	+ : rapid, sensitive and specific - : narrow range of pathogens detected	[52, 86-88]
<b>Xpert MRSA/SA BC</b> ( Cepheid, Sunnyvale, CA, USA)	Real-time PCR	1 hour	<i>S. aureus</i>	<i>mecA</i>	100 99-100 nr	+ : rapid, sensitive and specific - : expensive	[48, 49, 89-91]
<b>StaphSR assay</b> (BD GeneOhm, San Diego, CA, USA)	Multiplex PCR	1-2 hours	<i>S. aureus</i>	<i>mecA</i>	96-100 95-98 nr	+ : rapid, sensitive and specific - : expensive	[92, 93]
<b>StaphPlex</b> (Genaco Biomedical Products, Huntsville, AL, USA)	Multiplex PCR + Microarray	5 hours	<i>S. aureus</i>	<i>mecA</i> (+ PVL)	100 95-100 92	- : limited number of publications	[94]
<b>MALDI-TOF MS</b> Brucker Daltonics (Bremen, Germany) bioMérieux (Marcy l'Etoile, France)	Mass-spectrometry	<1 hour	<1000*	not in routine	- - 76-99	+ : rapid, sensitive and specific - : significant hands on time for bacterial enrichment	[32, 35, 53, 55, 56, 62, 65]

555

556

557

nr=non reported  
\*dependant on the mass-spectrum database